Stellar Biotechnologies Announces Investor Relations Agreement
Complete the form below to unlock access to ALL audio articles.
TheBiotechPanel is a full and comprehensive provider of investor relations services, and will assist the Company in fostering productive, continuing dialogues with analysts, brokers, investors and other financial professionals.
TheBiotechPanel will receive a monthly retainer of US $8,000 during the term of the IR Agreement ($48,000 for first six months). The IR Agreement is subject to review and approval by the TSX Venture Exchange.
Darrell Brookstein, Stellar's Executive VP, Corporate Development & Finance, said, "We are very pleased to have Frank Rothmaier, the founder and editor of TheBiotechPanel.com and his experienced partner, Ray Campos, on board to help Stellar reach out to European investors as we move forward with our U.S. registration which will enable a new group of professional investors and analysts to review the merits of our securities. TheBiotechPanel will bring 'biopharma fluency' in German and Spanish, and enable us to reach tens of thousands of European retail investors with demonstrated interest in U.S. small-cap biotech companies."
Frank Rothmaier, founder and Managing Director of TheBiotechPanel, said, "I have been enthusiastically following the dynamic Stellar growth story for almost two years now, and have been identifying investors for their KLH, therapeutic vaccine and potential active immune platform story during that time. I'm excited to bring the Stellar team to present before our European investors. I believe institutional as well as retail investors will become quite interested in Stellar Biotechnologies as it develops to the next stage in 2012."